UK markets closed

ABIONYX Pharma SA (0RAG.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
1.9460-0.1025 (-5.01%)
At close: 05:27PM GMT
Full screen
Previous close2.0485
Open1.9114
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range1.9114 - 1.9460
52-week range1.9114 - 1.9460
Volume3,201
Avg. volumeN/A
Market cap429,060
Beta (5Y monthly)0.30
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    ABIONYX Pharma: Press Release

    TOULOUSE, France & LAKELAND, Mich., February 03, 2023--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - eligible for PEA PME), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, announced today that it has been informed by TVM Capital of the total sale of their shares on the market due to the liquidation of their funds that have reached maturity.

  • Business Wire

    ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

    TOULOUSE, France & LAKELAND, Mich., January 16, 2023--ABIONYX Pharma (FR0012616852 – ABNX – PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today reported that the pilot Phase 2a clinical trial evaluating CER-001, the only natural recombinant apoA-I, as a treatment for septic patients at high risk of developing Acute Kidney Injury (AKI) met its primary objective. There are no approved treatments for septic patie

  • Business Wire

    ABIONYX Pharma Announces Its Financial Agenda for the Year 2023

    TOULOUSE, France & LAKELAND, Mich., January 13, 2023--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today announces its financial agenda for 2023.